Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPM.L Regulatory News (MPM)

  • There is currently no data for MPM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q1 Update

4 Apr 2019 07:00

RNS Number : 0683V
mporium Group PLC
04 April 2019
 

4 April 2019

Mporium Group plc

("Mporium" or the "Group")

Q1 Update

"Experienced significant growth"

Mporium Group plc (AIM: MPM), the technology firm delivering event-driven marketing, announces an update on trading during the first quarter of the financial year ("the Period").

Highlights:

· Outstanding growth following introduction of new business division, MporiumX

· Significant progress in monetisation of Allay's consumer claims opportunity

· Total revenues booked exceed £5.4m, with MporiumX accounting for 95%

· Reiteration of EBITDA break-even target during 2019

· Trading in line with management's expectations

The Company has experienced significant growth driven principally by the introduction of its new business division, MporiumX. Notably, the Company has announced a contract and subsequent contract expansion between MporiumX and a leading global sports media business, in addition to a transformational deal to become the exclusive supplier of customer acquisition and lead generation for Allay.

Trading continues to be pleasing and in-line with expectations. As an indicator of the step change undertaken by the business during the course of 2019, revenues booked during to the end of February 2019 exceeded £5.4m, of which the vast majority was business placed through MporiumX, and Mporium's Agency division showed a year-on-year increase of over 85%. The Company has a revolving working capital facility in place to support current strong growth expectations.

Significant progress has been made in the monetisation of Allay's consumer claims opportunity. MporiumX has seen growth in billed revenues during the first five weeks of operation and revenues are expected to increase materially over the coming months. In addition, IMPACT has already been deployed across several areas for performance marketing and lead generation, particularly on behalf of sports rights holders. The overall target is for MporiumX to achieve double-digit gross margins on lead generation.

In the Agency division, implementation of the IMPACT technology continues to grow. The division is firmly established within leading agency groups and is also experiencing significant traction outside the traditional agency roster in areas such as consultancy and recruitment. The gross margin delivered has been commensurate with previous period averages.

Financial outlook

The Company reiterates its target of EBITDA break-even during 2019, encouraged by greater than expected revenue growth in MporiumX. One critical underlying growth driver is the strong demand for lead generation within the consumer regulation sector. Mporium expects this growth to accelerate as a result of increasing regulation, consumer awareness and prescriptive compensation across many verticals. In addition, growth in the MporiumX division is also driven by lead generation for sports rights holders and additional targets include sectors such gambling and real estate.

Adoption of the IMPACT technology platform among our Agency clients is growing and is also expected to contribute significantly to the 2019 results. The rollout of an IMPACT self-serve solution for agencies is expected to significantly improve implementation and profitability of this business over the coming years.

Fully audited results for the financial year ended 31 December 2018 (which will not include the transformational growth of MporiumX) are expected to be announced in May.

CEO, Nelius De Groot, commented:

"This has been a transformational period for Mporium and we face the year ahead with increased optimism."

To learn more about Mporium, see the latest company presentation here:

https://cdn.mporium.com/app/uploads/2019/02/11204046/Company_Update_20190212.pdf 

Enquiries

 

Mporium:

020 3841 8411

Nelius De Groot, Chief Executive Officer

finnCap:

020 7220 0500

Henrik Persson / Kate Bannatyne (Corporate Finance)

Andrew Burdis (Corporate Broking)

Yellow Jersey PR:

020 3004 9512

Tim Thompson / Annabel Atkins / Felicity Winkles

 

Notes to editors

About Mporium

Mporium is a technology company at the forefront of the transformation in digital marketing. Mporium's proprietary technology enables advertisers, to identify and leverage moments when there are significant changes in the levels of consumer engagement. MporiumX is the performance-led moment marketing media trading division of Mporium Group.

Based in the UK, Mporium Group plc is quoted on AIM, the junior market of the London Stock Exchange plc.

www.mporium.com

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCDBGDSDXGBGCX
Date   Source Headline
27th Jun 20087:00 amRNSAHS Meeting
25th Jun 200810:28 amRNSDirector/PDMR Shareholding
24th Jun 200810:23 amRNSResult of Annual General Meet
24th Jun 20087:00 amRNSAGM Statement
16th Jun 20087:30 amRNSTEMPUS study fully enrolled
4th Jun 20087:00 amRNSAnnual Report and Accounts
2nd Jun 20087:00 amRNSUS Marketing Consultant
22nd May 20087:00 amRNSPreliminary Results
12th Mar 20087:00 amRNSAura trial fully enrolled
5th Feb 20087:00 amRNSTEMPUS Trial Update
3rd Dec 20077:00 amRNSInterim Results
16th Oct 20077:00 amRNSTEMPUS trial starts in US
4th Oct 200711:06 amRNSChange of Registered Office
28th Sep 200711:32 amRNSDirector/PDMR Shareholding
17th Aug 20077:00 amRNSAIM Rule 26
16th Jul 200711:29 amRNSResult of AGM
16th Jul 20077:00 amRNSAGM Statement
2nd Jul 20074:13 pmRNSHolding(s) in Company
27th Jun 20077:01 amRNSIHS Scientific Meeting
21st Jun 20075:05 pmRNSAnnual Report and Accounts
13th Jun 20077:02 amRNSPreliminary Results
7th Jun 20077:02 amRNSAHS Scientific Meeting
1st Jun 20078:30 amRNSTotal Voting Rights
18th May 20079:20 amRNSAdditional Listing
30th Apr 20076:22 pmRNSHolding(s) in Company
30th Apr 200712:16 pmRNSTotal Voting Rights
11th Apr 20074:39 pmRNSConversion of Loan Note
2nd Apr 20073:27 pmRNSHolding(s) in Company
2nd Apr 20072:55 pmRNSHolding(s) in Company
2nd Apr 20071:26 pmRNSDirector/PDMR Shareholding
30th Mar 20079:32 amRNSTotal Voting Rights
27th Mar 20077:01 amRNSBoard Appointments
26th Mar 200710:31 amRNSResult of EGM
2nd Mar 20077:30 amRNSGPB17m fundraising
9th Jan 20077:01 amRNSPositive Tonabersat Study
20th Dec 20065:43 pmRNSTotal Voting Rights
1st Dec 20067:01 amRNSInterim Results
17th Nov 20067:01 amRNSPlacing
25th Oct 200610:20 amRNSResult of AGM
25th Oct 20067:01 amRNSAGM Statement
27th Sep 20067:00 amRNSNIH Collaboration
20th Sep 20067:02 amRNSPreliminary Results
7th Sep 20067:00 amRNSAdditional Indications
15th Aug 200611:37 amRNSNotification of Interests
20th Jun 20067:00 amRNSStart of Phase II Trial
24th May 20067:01 amRNSUCLA Collaboration
21st Mar 20067:00 amRNSStart of Phase II Trial
8th Mar 20067:03 amRNSChange of Adviser
13th Jan 20067:00 amPRNRe Agreement
8th Dec 20057:00 amPRNInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.